Education
About Us
Working with TipRanks
Follow Us
Lifecore Biomedical (LFCR)
NASDAQ:LFCR
Top Page
Lifecore Biomedical
(NASDAQ:LFCR)
Select Model
Select Model
Rating:48Neutral
Price Target:
$8.00
▲(3.76% Upside)
Lifecore Biomedical's overall stock score is primarily impacted by its weak financial performance, characterized by high leverage and profitability issues. While technical analysis shows bullish momentum, the overbought RSI suggests caution. The negative P/E ratio further highlights valuation concerns. Strategic improvements in financial management are necessary to enhance the company's stability and attractiveness.
Lifecore Biomedical (LFCR) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$301.23M
Dividend YieldN/A
Average Volume (3M)204.26K
Price to Earnings (P/E)―
Beta (1Y)0.97
Revenue Growth0.47%
EPS Growth-430.88%
CountryUS
Employees524
SectorN/A
Sector StrengthN/A
IndustryDrug Manufacturers - Specialty & Generic
Share Statistics
EPS (TTM)-0.29
Shares Outstanding37,466,350
10 Day Avg. Volume178,832
30 Day Avg. Volume204,257
Financial Highlights & Ratios
PEG Ratio0.01
Price to Book (P/B)4.93
Price to Sales (P/S)1.82
P/FCF Ratio-17.18
Enterprise Value/Market Cap1.39
Enterprise Value/Revenue3.10
Enterprise Value/Gross Profit9.81
Enterprise Value/Ebitda-59.46
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusModerate Buy
Number of Analyst Covering4
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Lifecore Biomedical Business Overview & Revenue Model
Company DescriptionLifecore Biomedical (LFCR) is a leading medical technology company specializing in the development and manufacturing of advanced biomaterials and medical devices. The company operates primarily within the biotechnology and medical device sectors, focusing on regenerative medicine, particularly in the areas of orthopedic and dental applications. Lifecore's core products include hyaluronic acid-based injectable solutions, which are used in various surgical applications, as well as custom contract manufacturing services for other medical device companies.
How the Company Makes MoneyLifecore Biomedical generates revenue through multiple key streams. The primary source of income comes from the sale of its proprietary hyaluronic acid products, which are utilized in a range of medical procedures, including joint injections and surgical applications. Additionally, the company earns revenue through contract manufacturing services, where it partners with other medical firms to produce specialized products on a contractual basis. Significant partnerships with healthcare providers and medical device companies enhance Lifecore's market presence and contribute to its earnings by expanding its distribution channels and product offerings. Furthermore, the company's commitment to innovation and development of new medical technologies positions it to capture emerging market opportunities, thereby fostering growth in its revenue.
Lifecore Biomedical Earnings Call Summary
Earnings Call Date:Apr 03, 2025
(Q3-2025)
| % Change Since: |
Next Earnings Date:Jan 01, 2026
Earnings Call Sentiment Neutral
The earnings call highlighted significant strategic advancements in customer partnerships, pipeline progress, and operational efficiencies, suggesting a focus on long-term growth. However, the quarter experienced a decline in revenue and a net loss, influenced by specific non-recurring adjustments and increased SG&A expenses. Overall, the sentiment reflects cautious optimism, balancing growth initiatives with current financial challenges.Q3-2025 Updates
Positive Updates
Strong Customer Engagement and Expansion
Lifecore signed multiple new agreements with both new and existing customers, including a significant partnership with a large multinational partner poised to deliver a significant inflection point in volume demand in 2027.
Pipeline Advancements Towards Commercialization
10 of Lifecore's late-stage pipeline programs are poised for potential FDA approval by 2028. Significant milestones were achieved, including a statement of work with a large multinational partner and a PPQ campaign commitment.
Operational Efficiencies and Cost Reductions
Lifecore has improved production efficiencies, reduced operational expenses, and eliminated numerous consulting relationships. Enhanced productivity in direct labor areas and improved fermentation processing efficiency were noted.
Positive Cash Flow from Operations
The company achieved positive cash flow from operations of approximately $2 million during the quarter, despite one-time non-recurring expenses.
Negative Updates
Decrease in Quarterly Revenue
Revenues for the quarter decreased by 2% to $35.2 million compared to the prior year period, primarily due to a decrease in CDMO revenues.
Net Loss Compared to Prior Year
The company recorded a net loss of $14.8 million for the quarter compared to net income of $15.6 million in the previous year, attributed to the absence of a one-time favorable adjustment.
Increased SG&A Expenses
SG&A expenses increased primarily due to litigation expenses related to an activist investor matter and a securities class action lawsuit.
Company Guidance
During Lifecore's Fiscal 2025 Third Quarter Earnings Call, the company reiterated its financial guidance for the fiscal year, projecting revenues between $126.5 million and $130 million and an adjusted EBITDA ranging from $19 million to $21 million. The third quarter revenues were $35.2 million, a 2% decrease from the previous year, primarily due to a $1.5 million decline in CDMO revenues, offset by a $1 million increase in hyaluronic acid manufacturing revenues. The company reported a net loss of $14.8 million or $0.47 per diluted share, in contrast to a net income of $15.6 million or $0.42 per diluted share the previous year. Gross profit for the quarter was $9.8 million, down from $11.9 million, with a $2 million decline attributed to lower CDMO gross profit. Selling, general, and administrative expenses slightly increased to $10.1 million, with notable litigation expenses impacting the current period. Despite these challenges, Lifecore is focused on a 12% revenue CAGR and aims to improve EBITDA margins to over 25% in coming years, supported by strategic partnerships and new business ventures.Lifecore Biomedical Financial Statement Overview
Summary
Income Statement
45
Neutral
Balance Sheet
30
Negative
Cash Flow
40
Negative
| Breakdown |
|---|
Income Statement |
| Total Revenue |
| Gross Profit |
| EBITDA |
| Net Income |
Balance Sheet |
| Total Assets |
| Cash, Cash Equivalents and Short-Term Investments |
| Total Debt |
| Total Liabilities |
| Stockholders Equity |
Cash Flow |
| Free Cash Flow |
| Operating Cash Flow |
| Investing Cash Flow |
| Financing Cash Flow |
Lifecore Biomedical Technical Analysis
Positive
7.71
Price Trends
7.36
Positive
7.37
Positive
7.15
Positive
Market Momentum
0.19
Negative
56.17
Neutral
68.22
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For LFCR, the sentiment is Positive. The current price of 7.71 is below the 20-day moving average (MA) of 7.81, above the 50-day MA of 7.36, and above the 200-day MA of 7.15, indicating a bullish trend. The MACD of 0.19 indicates Negative momentum. The RSI at 56.17 is Neutral, neither overbought nor oversold. The STOCH value of 68.22 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for LFCR.
Lifecore Biomedical Peers Comparison
UnderperformOutperform
Sector (―)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| ― | ― | ― | ― | ― | ― | ― | |
57 Neutral | $213.56M | -21.43 | -47.05% | ― | 2.82% | 60.26% | |
55 Neutral | $65.96M | -18.92 | -13.08% | ― | 12.21% | 69.91% | |
54 Neutral | $509.18M | 20.27 | ― | ― | -10.42% | ― | |
48 Neutral | $301.23M | -6.17 | ― | ― | 0.47% | -430.88% | |
33 Underperform | $480.10M | -6.33 | -25.64% | ― | ― | -1.89% |
* Sector Average
LFCR
Lifecore Biomedical
8.04
1.01
14.37%
IRWD
Ironwood Pharma
3.13
-1.46
-31.81%
CPIX
Cumberland Pharmaceuticals
4.41
2.16
96.00%
SXTC
China SXT Pharmaceuticals
1.61
-1.16
-41.88%
DERM
Journey Medical Corp
7.87
3.32
72.97%
BIOA
BioAge Labs, Inc.
13.39
7.45
125.42%
Lifecore Biomedical Corporate Events
Executive/Board ChangesShareholder Meetings
Lifecore Biomedical Approves Key Proposals at Annual Meeting
Neutral
Oct 31, 2025
On October 29, 2025, Lifecore Biomedical held its annual meeting of stockholders, where three key proposals were addressed. Stockholders elected nine directors, ratified the appointment of KPMG LLP as the independent auditor for the fiscal year ending December 31, 2025, and approved the executive compensation package. These decisions are expected to influence the company’s governance and financial oversight, potentially impacting its strategic direction and stakeholder confidence.
Executive/Board ChangesBusiness Operations and Strategy
Lifecore Biomedical Approves New Cash Incentive Plan
Neutral
Sep 26, 2025
On September 22, 2025, Lifecore Biomedical‘s Compensation Committee approved a new cash incentive pay plan for the period from May 26, 2025, to December 31, 2025, due to a fiscal year change. This plan replaces the previously approved 2026 Bonus Plan and is designed to align executive bonuses with company financial performance goals, such as Adjusted EBITDA and total revenue, with a maximum bonus cap of 200% of the target level.
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.